Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07228832 · ClinicalTrials.gov registry record · Phase 3

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Phase 3 study of Metastatic Colorectal Cancer (CRC), sponsored by Summit Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
600
Enrollment target
20
Study locations

NCT07228832 is a Phase 3 study of Metastatic Colorectal Cancer (CRC) that is actively recruiting participants, run by Summit Therapeutics. The registered enrollment target is 600 participants, above the 107-participant average among 5 other Metastatic Colorectal Cancer (CRC) trials with a reported enrollment target (461% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07228832, a Phase 3 study of Metastatic Colorectal Cancer (CRC), is actively recruiting participants, sponsored by Summit Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
600 participants
Enrollment target
20
Study locations

Study Summary

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)

Conditions Studied

Metastatic Colorectal Cancer (CRC)

Interventions

  • DRUG Drug: Ivonescimab Injection
  • DRUG Drug: Bevacizumab Injection

Study Locations (20)

California

  • Clinical Study Site - Beverly Hills
  • Clinical Study Site - Cerritos
  • Clinical Study Site - Corona
  • Clinical Study Site - Duarte
  • Clinical Study Site - Huntington Beach
  • Clinical Study Site - Irvine
  • Clinical Study Site - Irvine
  • Clinical Study Site - Los Angeles
  • Clinical Study Site - Murrieta
  • Clinical Study Site - Orange
  • Clinical Study Site - Pasadena
  • Clinical Study Site - Torrance
  • Clinical Study Site - Upland
  • Clinical Study Site - West Hollywood

Connecticut

  • Clinical Study Site - New Haven
  • Clinical Study Site - Norwich

Florida

  • Clinical Study Site - Hialeah
  • Clinical Study Site - Port Saint Lucie

Arizona

  • Clinical Study Site - Goodyear

Georgia

  • Clinical Study Site - Newnan

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-11-18
Est. Completion 2029-11-30
Phase Phase 3

Sponsor

Summit Therapeutics

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07228832

The ClinicalTrials.gov registry entry for NCT07228832 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 107-participant average among 5 other Metastatic Colorectal Cancer (CRC) trials with a reported enrollment target (461% higher). The listed sponsor is Summit Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Colorectal Cancer (CRC) appearing as the primary indexed condition, and to 2 interventions - of which Drug: Ivonescimab Injection is the first listed.

NCT07228832 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Connecticut, Florida.

Frequently Asked Questions

What is clinical trial NCT07228832 about?

NCT07228832 is a clinical study titled "Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer". A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)

What is the current status of trial NCT07228832?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-11-18. Estimated completion is 2029-11-30.

What conditions does trial NCT07228832 study?

This clinical trial studies the following conditions: Metastatic Colorectal Cancer (CRC).

What interventions are being tested in trial NCT07228832?

The interventions under investigation include: Drug: Ivonescimab Injection (DRUG), Drug: Bevacizumab Injection (DRUG).

Who is sponsoring clinical trial NCT07228832?

This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07228832 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Colorectal Cancer (CRC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Colorectal Cancer (CRC)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.